Prescribing antiplatelet medicine and subsequent events after intracerebral hemorrhage

Stroke

Volumn 41, Issue 11, 2010, Pages 2606-2611

  Flynn, Robert W V ^a   MacDonald, Thomas M ^a   Murray, Gordon D ^b   MacWalter, Ronald S ^a   Doney, Alexander S F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

cardiovascular diseases; cerebral hemorrhage cohort study; platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPYRIDAMOLE;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; FEMALE; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; CEREBRAL HEMORRHAGE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SCOTLAND; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78149347732     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.589143     Document Type: Article

References (15)

1. Wani M, Nga E, Navaratnasingham R. Should a patient with primary intracerebral haemorrhage receive antiplatelet or anticoagulant therapy? BMJ. 2005;331:439-442.
2. Vermeer SE, Algra A, Franke CL, Koudstaal PJ, Rinkel GJ. Long-term prognosis after recovery from primary intracerebral hemorrhage. Neurology. 2002;59:205-209.
3. Sturgeon JD, Folsom AR, Longstreth WT Jr, Shahar E, Rosamond WD, Cushman M. Risk factors for intracerebral hemorrhage in a pooled prospective study. Stroke. 2007;38:2718-2725.
4. Wardlaw JM, Keir SL, Seymour J, Lewis S, Sandercock PA, Dennis MS, Cairns J. What is the best imaging strategy for acute stroke? Health Technol Assess. 2004;8:ix-iii,180.
5. Flynn R, MacDonald T, Murray G, Doney A. Systematic review of observational research studying the long-term use of antithrombotic medicines following intracerebral haemorrhage [published online ahead of print March 10 2010]. Cardiovasc Ther. 2010.
6. Wei L, Parkinson J, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO). In: Strom BL, ed. Pharmacoepidemiology. Chichester, UK: Wiley; 2005:xvii, 889.
7. Flynn RW, MacDonald TM, Murray GD, Ferguson C, Shah K, Doney A. The Tayside Stroke Cohort: exploiting advanced regional medical informatics to create a region-wide database for studying the pharmacoepide-miology of stroke. Pharmacoepidemiol Drug Saf. 2010;19:737-744.
8. Flynn RW, MacDonald TM, Schembri N, Murray GD, Doney A. Automated data capture from free-text radiology reports to enhance accuracy of hospital inpatient stroke codes. Pharmacoepidemiol Drug Saf. 2010;19:843-847.
9. Morris AD, Boyle DI, MacAlpine R, Emslie-Smith A, Jung RT, Newton RW, MacDonald TM. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic record linkage to create a diabetes register. DARTS/MEMO Collaboration. BMJ. 1997;315: 524-528.
10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324:71-86.
11. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemorrhage is more frequent than ischemic stroke after intracranial hemorrhage. Neurology. 2001;56:773-777.
12. Viswanathan A, Rakich SM, Engel C, Snider R, Rosand J, Greenberg SM, Smith EE. Antiplatelet use after intracerebral hemorrhage. Neurology. 2006; 66:206-209.
13. Hanger HC, Wilkinson TJ, Fayez-Iskander N, Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage. J Neurol Neurosurg Psychiatry. 2007;78:836-840.
14. Fogelholm R, Murros K, Rissanen A, Avikainen S. Long term survival after primary intracerebral haemorrhage: a retrospective population based study. J Neurol Neurosurg Psychiatry. 2005;76:1534-1538. (Pubitemid 41531701)
15. Morant SV, McMahon AD, Cleland JG, Davey PG, MacDonald TM. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol. 2004; 57:188-198.